China NMPA Drug Inspection - Bozhou Hongda Traditional Chinese Medicine Pieces Technology Co., Ltd. - Eucommia

The State Administration for Market Regulation issued Announcement No. 48 of 2017 on March 24, 2017, revealing significant regulatory findings. Inspections, primarily conducted by the Shaanxi Provincial Institute for Food and Drug Control, identified 35 batches of unqualified traditional Chinese medicine decoction pieces, specifically Eucommia ulmoides, from 34 enterprises. One of the implicated companies was Shaanxi Shangluo Panlong Botanical Pharmaceutical Co., Ltd., among many others across various regions. The core issue was that these batches failed to meet established quality standards. In response, provincial food and drug administrations were immediately directed to implement control measures, including sealing and seizing the substandard products, mandating sales and usage suspension, product recalls, and requiring comprehensive rectification from the manufacturers. Operating under Articles 73, 74, and 75 of the *Drug Administration Law of the People's Republic of China*, the State Food and Drug Administration mandated local administrations to investigate these illegal production and sale activities. Manufacturers had the right to object to findings, which would trigger further verification. The regulatory body required public disclosure of investigation results and penalties imposed on involved entities within three months, with severe penalties for confirmed infringements.